Capricor Therapeutics (CAPR) Operating Leases (2021 - 2026)

Capricor Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 3322.65% year-over-year to $13.9 million in Q1 2026; TTM through Mar 2026 was $13.9 million, a 3322.65% increase from a year earlier, with the FY2025 full-year figure at $14.3 million, up 2223.55% from the prior year.
• Operating Leases fell to $13.9 million in Q1 2026 per CAPR's latest filing, from $14.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $14.4 million in Q3 2025 and bottomed at $194603.0 in Q2 2025.
• The 5-year median for Operating Leases is $1.7 million (2023), against an average of $3.6 million.
• Across the five-year window, Operating Leases tumbled 81.36% in 2025 and soared 3322.65% in 2026, its largest moves.
• Year by year, Operating Leases stood at $1.9 million in 2022, then fell by 20.83% to $1.5 million in 2023, then tumbled by 58.55% to $616315.0 in 2024, then jumped by 2223.55% to $14.3 million in 2025, then declined by 2.63% to $13.9 million in 2026.
• Per Business Quant, the three latest CAPR Operating Leases figures stand at $13.9 million (Q1 2026), $14.3 million (Q4 2025), and $14.4 million (Q3 2025).